Literature DB >> 11866260

Impact of esophageal acid exposure on the endoscopic reversal of Barrett's esophagus.

Richard E Sampliner1, Lisa Camargo, Ronnie Fass.   

Abstract

OBJECTIVE: Normalization of esophageal acid exposure had been assumed to be necessary for the reversal of Barrett's esophagus with endoscopic therapy. This assumption is examined by evaluating the esophageal pH in a group of patients undergoing reversal therapy with fixed high-dose proton pump inhibitor therapy and endoscopic multipolar electrocoagulation (MPEC).
METHODS: Patients with Barrett's esophagus of 2-6 cm in length were treated with omeprazole (40 mg b.i.d.). They underwent 24-h esophageal pH monitoring 5 cm above the upper margin of the lower esophageal sphincter determined by a water-perfused catheter. They then underwent MPEC therapy to an endpoint of elimination of Barrett's (reversal) by both endoscopy and biopsy 6 months after the last MPEC session or failure to achieve visual (endoscopic) reversal after six treatment sessions.
RESULTS: Twenty patients had 24-h pH testing and reached a reversal endpoint. Three patients had abnormal pH tests, two total and supine and one supine only. These patients had documented reversal. The remaining 17 patients had normal pH testing but five failed reversal therapy.
CONCLUSION: Barrett's esophagus can be completely reversed with endoscopic therapy despite abnormal esophageal acid exposure. Also, patients can fail reversal even with normal esophageal acid exposure. The necessary reduction of esophageal acid exposure for reversal therapy has yet to be defined.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11866260     DOI: 10.1111/j.1572-0241.2002.05453.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  7 in total

Review 1.  The interplay between Helicobacter pylori, gastro-oesophageal reflux disease, and intestinal metaplasia.

Authors:  P Malfertheiner; U Peitz
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

Review 2.  Barrett's oesophagus and oesophageal adenocarcinoma: how does acid interfere with cell proliferation and differentiation?

Authors:  R C Fitzgerald
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

3.  Effective intra-esophageal acid control is associated with improved radiofrequency ablation outcomes in Barrett's esophagus.

Authors:  Junichi Akiyama; Samuel N Marcus; George Triadafilopoulos
Journal:  Dig Dis Sci       Date:  2012-08-10       Impact factor: 3.199

4.  A randomised controlled trial of ablation of Barrett's oesophagus with multipolar electrocoagulation versus argon plasma coagulation in combination with acid suppression: long term results.

Authors:  P Sharma; S Wani; A P Weston; A Bansal; M Hall; S Mathur; A Prasad; R E Sampliner
Journal:  Gut       Date:  2006-09       Impact factor: 23.059

Review 5.  Treatment for Barrett's oesophagus.

Authors:  Jonathan Re Rees; Pierre Lao-Sirieix; Angela Wong; Rebecca C Fitzgerald
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

6.  Prospective randomized trial of argon plasma coagulation ablation versus endoscopic surveillance of Barrett's esophagus in patients treated with antisecretory medication.

Authors:  Tim Bright; David I Watson; William Tam; Philip A Game; Roger Ackroyd; Peter G Devitt; Mark N Schoeman
Journal:  Dig Dis Sci       Date:  2009-12       Impact factor: 3.199

Review 7.  Barrett's oesophagus: optimal strategies for prevention and treatment.

Authors:  Ronnie Fass; Richard E Sampliner
Journal:  Drugs       Date:  2003       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.